News
As multiple large drugmakers look to navigate trade turbulence by pumping billions of dollars into their U.S. | Eli Lilly CEO ...
8h
GlobalData on MSNLilly’s Q1 2025 revenue jumps 45%, but CVS shift boosts Novo’s WegovyEli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) fell 11% in the afternoon session after the company reported ...
Eli Lilly CEO Dave Ricks took a stand against Trump's tariffs in a Q1 earnings call. The medicine company has strong operations for obesity and weight loss drugs in Ireland.
Eli Lilly (LLY) is among the list of large-cap pharmaceutical companies that are awaiting the Trump administration's word on ...
Starting on July 1, Wegovy will become the preferred GLP-1 for obesity treatment on CVS Caremark’s largest commercial ...
Ricks said reshoring manufacturing capacity for older essential medicines is “a valid thing,” adding that Eli Lilly is “happy ...
Eli Lilly revenue surged in the latest quarter on steady sales of Mounjaro and other weight-loss treatments in its portfolio.
The pharma industry’s reputation dropped slightly again among patient groups, largely due to drug pricing issues.
Eli Lilly (LLY) stock dips despite strong weight-loss drug sales as the company's Q1 2025 results fall short of forecasts.
Shares of Eli Lilly fell in premarket trading Thursday after the pharmaceutical giant's lowered profit projections outweighed ...
Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results